|
CN101115477A
|
|
Methods and materials with trans-clomiphene for the treatment of male infertility
|
|
KR20040043996A
|
|
Improved compositions for the treatment of Male Erectile Dysfunction
|
|
BR0204206A
|
|
Enhanced Compositions for the Treatment of Male Erectile Dysfunction
|
|
MXPA02010115A
|
|
Enhanced compositions for the treatment of male erectile dysfunction.
|
|
US2003004170A1
|
|
Combination therapy for modulating the human sexual response
|
|
JP2003012545A
|
|
Immunopotentiation inducible with chitosan
|
|
AU1974201A
|
|
Chitosan induced immunopotentiation
|
|
AU3967701A
|
|
Chitosan induced immunopotentiation
|
|
BR0009583A
|
|
Methods to modulate the sexual response in a human, and for the manufacture of a drug to modulate the sexual response in a human
|
|
AU3879200A
|
|
Methods and materials for the treatment of prostatic carcinoma
|
|
AU6049099A
|
|
Human chorionic gonadotropin vaccines
|
|
NZ335731A
|
|
Formulations for modulating the human sexual response comprising a vasodilator
|
|
AU3565799A
|
|
Methods and materials related to bioadhesive contraceptive gels
|
|
AU9716898A
|
|
Methods for modulating the human sexual response
|
|
US6482426B1
|
|
Compositions for the treatment of male erectile dysfunction
|
|
US6280742B1
|
|
Methods and materials for the treatment of prostatic carcinoma
|
|
BR9809848A
|
|
Composition
|
|
JPH10201493A
|
|
Preparaton and use of zone pellucida antigen and antibody for infertility and contraceptive
|
|
AU3481497A
|
|
Chitosan drug delivery system
|
|
EP0914154A1
|
|
Chitosan induced immunopotentiation
|
